Human Growth Hormone Market:
Human Growth Hormone Market is projected to be worth USD 12.29 Billion by 2030, registering a CAGR of 8.7% CAGR during the forecast period (2022-2030), the market was valued at USD 5.80 Billion in 2021. The GH deficiency segment led to the growth of the market. This can be ascribed to rising public knowledge of the early detection and treatment of human GH insufficiency. In 2021, the hospital pharmacy market held a substantial portion. This high percentage is ascribed to an increase in hospital visits as a result of growing public awareness of human GH insufficiency and its therapy. North America is predicted to make up the greatest portion of the market, due to excellent reimbursement conditions, and an established healthcare infrastructure.
Human Growth Hormone Market Dynamics:
Human growth hormone is a protein made by the body that is crucial throughout maturity as well as throughout childhood. The pituitary gland, called as “master gland” since it secretes numerous hormones that regulate the function of other glands, and produces growth hormones.
Driver:
The human growth hormone market is anticipated to be strongly influenced by elements such as investments made by market participants, the presence of a solid pipeline, extensive R&D activities, a strong product portfolio, and rising government efforts.
Restraints:
Stringent government approvals, strict guidelines, and expensive treatments are expected to restrain the growth and development of the human growth hormone market in the coming years.
Opportunity:
The factors such as a rise in disposable income, the surge in healthcare expenditure in developing economies, and mergers and acquisitions by market players are anticipated to create lucrative opportunities for the human growth hormone market.
COVID-19 Analysis of Human Growth Hormone Market:
The human growth hormone market has been severely impacted since the COVID-19 epidemic in many different parts of the world. Shipments were impacted during the initial lockdown due to a labor shortage and the closure of a manufacturing facility. The pandemic’s initial effects on China were tremendous. However, the nation’s circumstances have stabilized, and all product and service production rates have increased. As a result, it is determined that COVID-19’s overall impact on the human growth hormone market is moderate.
Human Growth Hormone Market Report Coverage:
| Report Attributes | Report Details |
| Study Timeline | 2016-2030 |
| Market Size in 2030 (USD Billion) | 12.29 |
| CAGR (2022-2030) | 8.7% |
| By Application | Growth Hormone (GH) Deficiency – Adult GH Deficiency, Pediatric GH Deficiency
Turner Syndrome , Idiopathic Short Stature, Prader-Willi Syndrome, Small for Gestational Age, Other |
| By Distribution Channel | Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Specialty Pharmacy |
| By geography | North America– (U.S., Canada, Mexico
Europe- (Germany, France, U.K., Russia, Italy, Spain, BENELUX, Rest of Europe) Asia Pacific- (China, Japan, India, South Korea, Australia, ASEAN, Rest of Asia Pacific) Latin America- (Brazil, Argentina, Chile, Rest of Latin America) The Middle East and Africa- (GCC, Turkey, Israel, Rest of MEA) |
| Key Players | Novo Nordisk A/S, Pfizer, Inc, Eli Lilly and Company, Sandoz International GmbH (Novartis AG), Merck KGaA, Genentech, Inc (Roche), Ferring Pharmaceuticals, Teva Pharmaceutical Industries, Ltd, Ipsen. |
Human Growth Hormone Market Segment Analysis:
By Application
The market share of application segment in 2021 was dominated by the GH deficiency segment, and it is anticipated that it will continue to dominate during the projected period. This can be ascribed to rising public knowledge of the early detection and treatment of human GH insufficiency as well as the entry of new medications onto the HGH market. For instance, TransCon HGH, an experimental long-acting GH medication for humans with a juvenile GH deficient indication, was granted Orphan Designation by the European Commission (EC) in October 2018.
Similar to this, Ferring Pharmaceuticals Inc.’s novel recombinant human growth hormone, Zomacton (somatropin), was approved by the USFDA in January 2018 to treat individuals with GH insufficiency. The pediatric GH deficiency sector is expected to lead the human growth hormone market due to the growing sum of pipeline medications. The GH deficiency segment is further divided into pediatric GH deficiency and adult GH deficiency. In 2019, for example, Pfizer Inc. and its collaborator OPKO Health Inc. declared that the primary endpoint of their Phase III study testing Somatrogon’s non-inferiority to daily somatropin in pre-pubertal children with human growth hormone had been fulfilled.
By Distribution Channel
The market for human growth hormones has been divided into hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies based on the distribution channel. In 2021, the hospital pharmacy market held a substantial portion. This high percentage is ascribed to an increase in hospital visits as a result of growing public awareness of human GH insufficiency and its therapy. Further, online pharmacy segment is expected to be the second dominating region in the human growth hormone. Further, segments such as retail pharmacy, online pharmacy, specialty pharmacy are expected to fuel the growth of the human growth hormone market.
By Region
The regional segment of the human growth hormone market includes regions such as Asia Pacific, North America, Europe, the Middle East, Africa, and Latin America. North America is predicted to make up the greatest portion of the market, due to excellent reimbursement conditions, an established healthcare infrastructure, considerable government initiatives, and rising healthcare awareness. The presence of major firms in the area also facilitates greater access to innovative medications, which benefits the North American market. Several major companies with U.S. headquarters, including Pfizer, Inc., Eli Lilly and Company, and Genentech, Inc., provide a variety of human GH medicines in the area.
Human Growth Hormone Market Competitive Landscape:
The competitive landscape of the market has been analyzed in the report, along with the detailed profiles of the major players operating in the industry. Further, the surge in Research and Development (R&D), product innovation, various business strategies, and Application launches have accelerated the growth of the Human Growth Hormone Market. Key players in the market include-
- Novo Nordisk A/S
- Pfizer, Inc.
- Eli Lilly and Company
- Sandoz International GmbH (Novartis AG)
- Merck KGaA
- Genentech, Inc (Roche)
- Ferring Pharmaceuticals
- Teva Pharmaceutical Industries, Ltd
Table of Content
- Introduction
- Market Introduction
- Market Research Methodology
- Research Process
- Primary Research
- Secondary Research
- Data Collection Technique
- Data Sources
- Market Estimation Methodology
- Limitations of the Study
- Product Picture of Human Growth Hormone
- Global Human Growth Hormone Market: Classification
- Geographic Scope
- Years Considered for the Study
- Research Methodology in brief
- Parent Market Overview
- Overall Human Growth Hormone Market Regional Demand
- Research Programs/Design
- Market Breakdown and Data Triangulation Approach
- Data Source
- Secondary Sources
- Primary Sources
- Primary Interviews
- Average primary breakdown ratio
- Market Dynamics
- Drivers
- Drivers
- Restraints
- Restraints
- Opportunity
- Impact forces on market dynamics
- Impact forces during the forecast years
- Industry Value Chain
- Upstream analysis
- Downstream analysis
- Therapeutic
- Direct Channel
- Indirect Channel
- Potential Customers
- Manufacturing/Operational Cost Analysis
- Pricing Analysis by Region
- Key Application Landscape
- Regulatory Analysis
- Porter’s Analysis
- Supplier Power
- Buyer Power
- Substitution Threat
- Threat from New Entry
- Competitive Rivalry
- PESTEL Analysis
- Political Factors
- Economic Factor
- Social Factors
- Technological Factor
- Environmental Factors
- Legal Factor
- Covid-19 impact on Global Economy
- Covid-19 impact on Human Growth Hormone Market demand
- Post-Covid Impact on Human Growth Hormone Market Demand
- Impact Analysis of Russia-Ukraine Conflict
- Drivers
- Global Human Growth Hormone Market Segmentation, Revenue (USD Billion), (2022-2030)
- By Application
- Growth Hormone (GH) Deficiency
- Adult GH Deficiency
- Pediatric GH Deficiency
- Turner Syndrome
- Idiopathic Short Stature
- Prader-Willi Syndrome
- Small for Gestational Age
- Other
- Growth Hormone (GH) Deficiency
- By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Specialty Pharmacy
- By Application
- Global Human Growth Hormone Market Overview, By Region
- North America Human Growth Hormone Market Revenue (USD Billion), by Countries, (2022-2030)
- US
- By Application
- By Distribution Channel
- Canada
- Mexico
- US
- Europe Human Growth Hormone Market Revenue (USD Billion), by Countries, (2022-2030)
- France
- UK
- Spain
- Russia
- Italy
- BENELUX
- Asia Pacific Human Growth Hormone Market Revenue (USD Billion), by Countries, (2022-2030)
- China
- Japan
- Australia
- South Korea
- India
- ASEAN
- North America Human Growth Hormone Market Revenue (USD Billion), by Countries, (2022-2030)
- Latin America Human Growth Hormone Market Revenue (USD Billion), by Countries, (2022-2030)
- Brazil
- Argentina
- Chile
- Middle East and Africa Human Growth Hormone Market Revenue (USD Billion), by Countries, (2022-2030)
- GCC
- Turkey
- South Africa
- Global Human Growth Hormone Market Revenue: Competitive Analysis, 2021
- Key strategies by players
- Revenue (USD Billion and %), By manufacturers, 2021
- Player Positioning by Market Players, 2021
- Competitive Analysis
- Novo Nordisk A/S
- Business Overview
- Business Financials (USD Billion)
- Application Category, Source, and Specification
- Main Business/Business Overview
- Geographical Analysis
- Recent Development
- Swot Analysis
- Pfizer, Inc
- Eli Lilly and Company
- Sandoz International GmbH (Novartis AG)
- Merck KGaA
- Genentech, Inc (Roche)
- Ferring Pharmaceuticals
- Teva Pharmaceutical Industries, Ltd
- Novo Nordisk A/S
- Market Research Findings & Conclusion
Disclaimer
Research Methodology
The Market Research Community offers numerous solutions and its full addition in the research methods to be skilled at each step. We use wide-ranging resources to produce the best outcome for our customers. The achievement of a research development is completely reliant on the research methods implemented by the company. We always faithful to our clients to find opportunities by examining the global market and offering economic insights.Market Research Community are proud of our widespread coverage that encompasses the understanding of numerous major industry domains. Company offers consistency in our research report, we also offers on the part of the analysis of forecast across a range of coverage geographies and coverage. The research teams carry out primary and secondary research to carry out and design the data collection methods.